GSK’s ex-vaccines chief says its jab for a flu-like ... - Financial Times
网页1 天前 · GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn and winter is too expensive and difficult to use after raising $100mn for a rival start-up to ...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
网页6 天之前 · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
GSK Announces Positive Topline Data on Co-Administration of …
网页PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine …
Press releases - GSK
网页Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK makes a strong start to 2024 with improving outlook for the …
网页2024年5月1日 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of …
GSK readies for pivotal ruling in Zantac cases - Financial Times
网页2024年4月24日 · The federal court in Florida found that plaintiffs’ scientists’ findings were based on “unreliable methodologies”, in effect dismissing almost 2,500 cases in 2022, a decision that GSK said ...
GSK shares fall as US narrows age recommendation for RSV vaccines
网页2024年6月27日 · GSK shares fell more than 6 per cent on Thursday morning after US health officials recommended restricting the use of vaccines for respiratory syncytial virus, an area in which the British ...
Press releases | GSK US
网页US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
GSK News
网页Stay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
网页2023年5月3日 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first …